Fibrocyte accumulation in bronchi: a cellular hallmark of COPD

Isabelle Dupin^{1,2,*}, Matthieu Thumerel^{1,2,3,*}, Elise Maurat^{1,2}, Florence Coste^{1,2}, Hugues Begueret³,
Thomas Trian^{1,2}, Michel Montaudon^{1,2,3}, Roger Marthan^{1,2,3}, Pierre-Olivier Girodet^{1,2,3}, Patrick
Berger^{1,2,3}

¹Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Département de
Pharmacologie, CIC 1401, F-33000 Bordeaux, France

²INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, CIC 1401, F-33000
Bordeaux, France

³CHU de Bordeaux, Service d'exploration fonctionnelle respiratoire, Service de chirurgie
thoracique, Service d'anatomopathologie, Service de radiologie, CIC 1401, F-33604 Pessac,
France

* equal contribution (co-1st author)

Corresponding author: Isabelle Dupin,

Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, 146 rue Leo Saignat
Zone, F-33000 Bordeaux, France

Telephone number : +33 5 57 57 16 94 Fax number : +33 5 57 57 16 95

e-mail: isabelle.dupin@u-bordeaux.fr

Disclosure of potential conflict of interest:

I. Dupin has received research support from Fondation Bordeaux Université. P-O. Girodet has
received research support from Novartis, Chiesi, Boehringer Ingelheim, GlaxoSmithKline and
AstraZeneca outside the submitted work. P. Berger has received research support from Nycomed,

27 Takeda, Fondation du Souffle–Fonds de dotation Recherche en Santé Respiratoire, Novartis, Pierre
 28 Fabre, Chiesi, Boehringer Ingelheim, AstraZeneca, and GlaxoSmithKline. I. Dupin, P. Berger and
 29 P-O. Girodet have a patent pending (EP No. 15152886.6; ie, New compositions and methods of
 30 treating and/or preventing chronic obstructive pulmonary disease).The rest of the authors declare
 31 that they have no relevant conflicts of interest.

32
 33 **Funding:** This study was sponsored and supported by Bordeaux University Hospital (*i.e.* “CHU
 34 de Bordeaux”). This study was supported by a grant from the “Fondation Bordeaux Université”,
 35 with funding from "Assistance Ventilatoire à Domicile" (AVAD) and "Fédération Girondine de
 36 Lutte contre les Maladies Respiratoires" (FGLMR).

Abstract

Background

The remodeling mechanism and cellular players causing persistent airflow limitation in chronic obstructive pulmonary disease (COPD) remain largely elusive. We have recently demonstrated that circulating fibrocytes, a rare population of fibroblast-like cells produced by the bone marrow stroma, are increased in COPD patients during an exacerbation. It remains, however, unclear, whether fibrocytes are present in bronchial tissue of COPD patients.

Objective

We aimed to quantify fibrocytes density in bronchial specimens from both control subjects and COPD patients, and to define associations with clinical, functional and computed tomography relevant parameters.

Methods

17 COPD patients and 25 control subjects with normal lung function testing and no chronic symptoms, all of them requiring thoracic surgery, were recruited. LFT and CT-scan were performed before surgery. Using co-immunostaining and image analysis, we identify CD45⁺ FSP1⁺ cells as tissue fibrocytes and quantify their density in distal and proximal bronchial specimens from the whole series.

Results

Here, we demonstrate that fibrocytes are increased in both distal and proximal tissue specimens of COPD patients, compared to those of controls. The density of fibrocytes is negatively correlated with lung function parameters, such as FEV1 and FEV1/FVC, and positively with bronchial wall thickness assessed by CT scan. High density of distal bronchial fibrocytes predicts presence of COPD with a sensitivity of 83% and a specificity of 70%.

Conclusions

61 Our results thus suggest that recruitment of fibrocytes in the bronchi may participate to lung
62 function decline during COPD progression.

63

64 **Number of words in the abstract:** 239

65 **Clinical Implications**

66 High density of tissue fibrocytes is associated with a deteriorated lung function and an increase in
67 airway wall thickness. A low density tissue fibrocytes virtually eliminates the presence of COPD.

68
69 **Capsule summary**
70
71 Blood fibrocytes assessed during exacerbation is a predictor of mortality in COPD. This study
72 shows an increase of bronchial fibrocytes, that is associated with lower lung function, increased
73 bronchial thickness and air trapping in COPD.

74
75 **Key words:** COPD, lung function, away remodeling, CT scan, fibrocytes

76 **Abbreviations**

77		
78	APC	Allophycocyanin
79		
80	BEC	Bronchial Epithelial Cells
81		
82	CSA	Cross Section Area
83		
84	CSN	Cross Section Number
85		
86	GOLD	Global Initiative for Chronic Obstructive Lung Disease
87		
88	COPD	Chronic Obstructive Pulmonary Disease
89		
90	CT	Computed tomography
91		
92	FEV₁	Forced Expiratory Volume in 1 second
93		
94	FITC	Fluorescein isothiocyanate
95		
96	FVC	Forced Vital Capacity
97		
98	FSP1	Fibroblast-Specific Protein 1
99		
100	LA	Lumen Area
101		
102	LAA	Low Attenuation Area
103		
104	MLA	Mean Lung Attenuation
105		
106	PaCO₂	Arterial Partial Pressure of Carbon Dioxide
107		
108	PaO₂	Arterial Partial Pressure of Oxygen
109		
110	PE	Phycoerythrin
111		
112	PBMC	Peripheral Blood Mononuclear Cells
113		
114	TLCO	Transfer Lung capacity of Carbon monoxide
115		
116	WA	Wall Area
117		
118	WT	Wall Thickness
119		

Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by chronic persistent inflammation and remodeling leading to progressive airflow limitation (1, 2). The evolution of this chronic disease is worsened by acute exacerbations, frequently triggered by viral or bacterial infections (3). These exacerbations are considered as an independent prognostic factor for mortality (4). Current pharmacological treatments for COPD patients decrease exacerbation frequency by only up to 29% as compared to placebo either alone or in combination, but they do not have any significant effect on mortality (5-7). COPD patients exhibit remodeling processes leading to permanent changes in tissue structure, such as epithelial mucous metaplasia, parenchymal destruction (*i.e.*, emphysema) and connective-tissue deposition in the small airway walls (1). This latter, also called peribronchiolar fibrosis, has been observed even in young smokers (8), thus suggesting that it may be an initiating event in COPD pathophysiology. To date, these processes are not inhibited or reversed by current pharmacotherapy.

Fibrocytes are fibroblast-like cells produced by the bone marrow stroma and released in the peripheral circulation (9). Circulating fibrocytes, defined as CD45⁺ collagen I⁺ cells, are increased in COPD patients only during an exacerbation (10) and not in stable state, as compared to control subjects (10, 11). A high blood fibrocytes concentration during an exacerbation is associated with an increased risk of death (10), suggesting a deleterious role of fibrocytes in COPD evolution. By contrast, myeloid derived suppressor cells (MDSC)-like fibrocytes, a subpopulation of circulating fibrocytes, are increased in the blood of stable COPD patients, and these cells might rather play a protective role (11). The presence and the role of fibrocytes in the lung of COPD patients remain controversial (11) and need to be clarified. Indeed, tissue fibrocytes, defined as CD34⁺ collagen I⁺ cells, have not been found in distal airways of COPD patients, and detected in proximal airways of only less than 50% of COPD patients (11). However, fibrocytes are known to downregulate CD34

expression when differentiating (12). Thus, the co-expression of CD34 and collagen I, as a definition criterion for tissue fibrocyte, may lead to fibrocytes underestimation (11). As a consequence, we define fibrocytes as cells double positive for both CD45 and fibroblast-specific protein 1 (FSP1), in agreement with previous reports from human (13) and mice (14-16) lungs. Thus, the aim of the present study was to determine the density of tissue fibrocytes (*i.e.*, CD45⁺ FSP1⁺ cells) in distal and proximal airway specimens of COPD patients, as compared to that in control subjects. We then evaluated the relationship between the density of tissue fibrocytes and parameters derived from lung function test and quantitative computed tomography (CT) as well as with blood fibrocytes. Functional *in vitro* experiments were also performed to assess the effect of epithelial microenvironment on fibrocyte survival.

Methods

A more detailed description of methods is provided in the online supplement.

Study populations

Subjects aged more than 40 years were eligible for enrolment if they required thoracic surgery lobectomy for cancer pN0, lung transplantation or lung volume reduction. A total of 17 COPD patients, with a clinical diagnosis of COPD according to the GOLD guidelines (2) and 25 non COPD subjects (“control subjects”) with normal lung function testing (*i.e.*, FEV₁/FVC > 0.70) and no chronic symptoms (cough or expectoration) were recruited from the University Hospital of Bordeaux.

To study fibrocytes *in vitro*, blood samples were obtained from a separate cohort of COPD patients, the COBRA cohort (“Cohorte Obstruction Bronchique et Asthme”; Bronchial Obstruction and

Asthma Cohort; sponsored by the French National Institute of Health and Medical Research, INSERM) (Tables E3 and E5).

Study design

This clinical trial was sponsored by the University Hospital of Bordeaux. The study has been registered at ClinicalTrials.gov under the N° NCT01692444 (*i.e.* “Fibrochir” study). The study protocol was approved by the local research ethics committee on May 30, 2012 and the French National Agency for Medicines and Health Products Safety on May 22, 2012. All subjects provided written informed consent. The study design is summarized in Fig E1. 4 visits were scheduled: a pre-inclusion visit (V1) to explain study and surgery, an inclusion visit (V2) the day of surgery, a visit one month $\pm$ 15 days after surgery (V3), and a the last visit one year $\pm$ 15 days after surgery (V4).

Bronchial fibrocytes identification

A sub-segmental bronchus sample (for proximal tissue) as well as fragments of distal parenchyma were obtained from macroscopically normal lung resection material. The samples were embedded in paraffin and sections of 2.5 μ m thick and were stained with both rabbit anti-FSP1 polyclonal antibody (Agilent) and mouse anti-CD45 monoclonal antibody (BD Biosciences, San Jose, CA), or mouse anti-CD3 monoclonal antibody (Agilent), mouse anti-CD19 monoclonal (Agilent), mouse anti-CD34 monoclonal antibody (Agilent). The sections were imaged using a slide scanner Nanozoomer 2.0HT (Hamamatsu Photonics, Massy, France). Quantification of dual positive cells for FSP1 and CD45 was performed as described in Fig 1. The density of FSP1⁺ CD45⁺ cells was defined by the ratio between the numbers of dual positive cells in the lamina propria divided by lamina propria area. Quantification of dual positive cells for FSP1 and CD3, FSP1 and CD19 or

FSP1 and CD34 was performed, as described above with some modification (see Supplemental Material and Methods in the online data supplement). Tissue area and cell measurements were all performed in a blinded fashion for patients' characteristics.

Quantitative computed tomography

CT scans were performed on a Somatom Sensation Definition 64 (Siemens, Erlangen, Germany) at full inspiration and expiration and analyzed using dedicated and validated software, as described previously (17-20)

Circulating fibrocytes identification

Non-adherent non-T (NANT) cells were purified from Peripheral Blood Mononuclear Cells (PBMC) separated from the whole blood, and circulating fibrocytes were identified as double positive cells for the surface marker CD45 and the intracellular marker collagen I by flow cytometry, as described previously (10).

Bronchial epithelial supernatants

Human bronchial epithelial cells (BEC) were derived from bronchial specimens (see Table E4 for patients' characteristics), as described previously (21). Basal epithelial supernatant from fully differentiated epithelium was collected for further experiments.

Fibrocyte differentiation and survival

NANT cells purified from blood samples of COPD patients (Table E3 and E5) were incubated during one week in DMEM (Fisher Scientific) supplemented with 20% fetal calf serum (Biowest, Riverside, USA), followed by another week in serum-free medium, or serum-free medium

containing 50% of basal epithelial supernatant. After 2 weeks in culture, the cells were detached by accutase (Fisher Scientific), and either fixed overnight with Cytofix/Cytoperm and stained to assess CD45, FSP1 and collagen I expression or directly stained by propidium iodide (PI) to assess the level of dead cells (PI⁺ cells), by flow cytometry.

Statistical analysis

Values are presented as means $\pm$ SD or the medians (95% confidence interval [CI]). Statistical significance, defined as $P < 0.05$, was analyzed by Fisher's exact tests for comparison of proportions, by two-sided independent t-tests for variables with a parametric distribution, and, by Wilcoxon tests, Mann–Whitney U tests and Spearman correlation coefficients for variables with a non-parametric distribution. Receiver operating characteristic (ROC) analysis and a univariate logistic regression analysis was performed to evaluate the association between COPD and a high density of tissue fibrocytes.

Results

Study population

The number of patients enrolled, excluded or followed for up to 1 year after surgery is shown in supplemental Fig E1. Clinical and functional characteristics, as well as quantitative CT parameters of all subjects with tissue fibrocytes assessment are shown in Table 1. The groups of control and COPD patients were well matched for age and body mass index. As expected, COPD patients were significantly different from controls in terms of smoking habits, lung function (FEV₁, FVC, FEV₁/FVC ratio, RV), diffusing capacity (TLCO) and CT parameters including wall thickness, emphysema extent (LAA), air trapping (MLA E) and cross-sectional pulmonary vessel area and number (CSA, CSN) (Table 1).

Bronchial fibrocytes are increased in COPD patients

As a methodological control, we first cultured fibrocytes from blood samples coming from a separate cohort of COPD patients (Table E3), and we showed that virtually all the CD45⁺ FSP1⁺ cells (99.9 ± 0.06%) purified from circulating PBMC also express collagen I after 14 days of cell differentiation *in vitro* (Fig E2). This allows us to define tissue fibrocytes as CD45⁺ FSP1⁺ cells. These cells were identified by immunohistochemistry as shown in Fig 1, and they were detected in distal tissue specimens from 11 of 12 COPD patients (92%) and 13 of 20 control subjects (65%) (Fig 2) as well as in proximal tissue specimens from 14 of 14 COPD patients (100%) and 16 of 21 control subjects (76%) (Fig 3).

These fibrocytes were located in the sub-epithelial region of both distal and proximal airways (Figs 2A and 3A) and, occasionally, within the epithelial layer. No CD45⁺ FSP1⁺ cell was evidenced within the airway smooth muscle layer. Some tissue fibrocytes were found in peribronchial area outside the smooth muscle layer (Fig E3). However, the analysis of fibrocyte density in this latter

region could not be performed systematically, since this area could not be identified in each of our tissue specimens. The density of bronchial fibrocytes was higher in the subepithelial region of distal airways from COPD patients (median = 133 cells/ μm^2 (95% CI, 40 to 469), $n = 12$) than in that of control subjects (median = 42 cells/ μm^2 (95% CI, 31 to 114), $n = 20$, $P < 0.05$) (Fig 2B). Similarly, fibrocytes density was also increased in the proximal airways from COPD patients (median = 73 cells/ μm^2 (95% CI, 47 to 139), $n = 14$) compared with control subjects (median = 21 cells/ μm^2 (95% CI, 18 to 60), $n = 21$, $P < 0.05$) (Fig 3B). In both distal and proximal airways, there was no difference in sub-epithelial areas considered for tissue fibrocytes quantification between COPD patients and control subjects (Figs 2C and 3C). Not surprisingly, however, the density of fibrocytes in the sub-epithelial area of proximal tissue was positively and significantly correlated with that measured in distal airways (Fig E4).

To further confirm our results, we co-stained FSP1 with CD3 or CD19 to determine whether FSP1 positive cells could be T-lymphocytes or B-lymphocytes, respectively. Except for one control subject, very few CD3⁺ cells also expressed FSP1 (Fig E5A), and there was no significant difference in the density of CD3⁺ FSP1⁺ cells in the sub-epithelial region of distal airways between controls and COPD patients (Fig E5B-C). Likewise, this density was not statistically different between both groups in proximal airways (Fig E5D-E). The B-lymphocyte CD19 marker co-localized with FSP1 positive cells neither in distal (Fig E6A) nor in proximal (Fig E6B) tissue specimens. We also co-immunostained CD34 and FSP1. CD34⁺ FSP1⁺ cells were detected in distal tissue specimens, from only 2 of 12 COPD patients (17%) and 4 of 20 control subjects (20%) (Fig E7). CD34⁺ FSP1⁺ cells were found in proximal tissue specimens from 9 of 13 COPD patients (69%) and 11 of 21 control subjects (52%) (Fig E8), but the density of these cells in COPD patients (median = 0.5 cells/ μm^2 (95% CI, 0.1 to 1.7), $n = 13$) was very low compared with that of CD45⁺ FSP1⁺ cells (median = 73 cells/ μm^2 (95% CI, 47 to 139), $n=14$) (Fig 2B). In both distal and

proximal airways, there was no difference in the density of CD34⁺ FSP1⁺ cells between COPD patients and control subjects (Figs E7 and E8).

Relationships between bronchial fibrocytes density and functional and CT parameters

We first determined univariate correlation coefficients between the density of tissue fibrocytes in the subepithelial region of both distal and proximal airways and various functional and CT parameters (Tables E1 and E2). In distal tissue specimens, the density of fibrocytes was negatively correlated to FEV₁/FVC ratio (Fig 4A) and positively to PaCO₂ (Fig 4B). It was also significantly associated with mean lung attenuation value during exhalation (Fig 4C). In proximal tissue specimens, the density of fibrocytes was negatively correlated to FEV₁ (Fig 4D), FVC (Table E2), and positively correlated to RV (Table E2), WT4 (Fig 4E), WT5 (Fig 4F), WA4% (Table E2).

Receiver Operator Characteristic (ROC) curves were built for all subjects whose density of tissue fibrocytes has been assessed in distal (n=12 COPD patients and 20 control subjects, Fig 5A) and proximal (n=14 COPD patients and 21 control subjects, Fig 5B) tissue specimens with significant areas under the curves (Table 2). To predict COPD, the density of fibrocytes in distal airways has a sensitivity of 83% and a specificity of 70%, whereas this density has a sensitivity of 79% and a specificity of 67% in proximal airways (Table 2). Moreover, the negative predictive value to eliminate COPD was 97.5% and 96.6% for distal and proximal airways, respectively, using a prevalence of 10% for COPD in the general population (22). ROC analyses allowed us to select the optimal value of fibrocytes density (cut-off values of 72 and 32 for distal and proximal tissue, respectively) to classify patients either with a high or low level of tissue fibrocytes (Table 2). COPD was associated with a high density of fibrocytes in distal (odds ratio: 11.7; 95% CI: [1.9-70.2]; P < 0.05) and proximal (odds ratio: 7.3; 95% CI: [1.5-35.1]; P < 0.05) airways. Thus, a high tissue fibrocytes density is associated with a higher risk of COPD.

Circulating fibrocytes are unchanged in stable COPD

The percentage of blood fibrocytes (CD45⁺ ColI⁺ cells) in PBMC, was not statistically different in stable COPD patients (median=10.3% (95% CI, 4.6 to 16.5) of PBMC, n=12) and control subjects (median=7.9% (95% CI, 4.1 to 11.6) of PBMC, n=22) (Fig E9A). A similar result was obtained when fibrocytes concentration is expressed as absolute counts per milliliter of blood (data not shown). Finally, the percentage of blood fibrocytes (*i.e.*, CD45⁺ ColI⁺ cells) in PBMC was significantly correlated with the density of bronchial fibrocytes (*i.e.*, CD45⁺ FSP1⁺ cells) in distal airways (Fig E9B).

COPD epithelial supernatant favors fibrocytes survival

We next investigated whether secretion from bronchial epithelial cells (BEC) from control or COPD patients could affect fibrocytes viability or ECM secretion in an *in vitro* assay. We evaluated this effect using BEC obtained from lung resection material sampled either in control subjects (n=2) or in COPD patients (n=2) (Table E4), cultured at the air-liquid interface. Fibrocytes were cultured from blood samples coming from a separate cohort of 6 COPD patients (Table E5). 7 to 10 days after blood sampling, cells, almost all being CD45⁺ FSP1⁺ cells ($94.9 \pm 3.6\%$), were exposed during 7 days to a mixture of fully differentiated BEC supernatants coming either from control subjects or COPD patients. 7 days after initial exposure, the level of CD45⁺ FSP1⁺ cells remains high ($92.9 \pm 3.9\%$ and $93.4 \pm 3.3\%$ respectively for the control and COPD conditions). However, exposure of fibrocytes to COPD epithelial supernatant significantly decreased the percentage of dying cells (Fig E10).

Discussion

In the present study, we have shown that the density of tissue fibrocytes (*i.e.*, CD45⁺ FSP1⁺ cells) is significantly greater in both distal and proximal airway specimens of COPD patients, as compared to that of control subjects. We also found a significant correlation between this tissue fibrocytes density with blood fibrocytes as well as airflow obstruction, increased wall thickness, or air trapping. By means of ROC curve analysis and univariate logistic regression analysis, we observed that a high density of tissue fibrocyte increases the likelihood of COPD. Finally, it appears that fibrocytes survival is increased by epithelial cells secretion from COPD patients, a mechanism that could contribute to the elevated sub-epithelial density of fibrocytes in COPD patients.

There is an discrepancy between the present results and those previously obtained by Wright and colleagues (11), which deserves some methodological discussion. Wright *et al* did not find an increased level of tissue fibrocytes in COPD patients. They did not even observe any fibrocyte in distal airways (11). However, the methodology of tissue fibrocytes assessment and, ultimately, the definition of fibrocytes, are different in the present study and in that of Wright *et al* (11). Wright and colleagues' method relied on the identification of CD34 and collagen I staining on sequential, instead of identical, sections (11) which could lead to either, false fibrocytes identification because of apparent co-expression in closely apposed but not identical cells, or fibrocytes underestimation because of the absence of co-expression in cells that are present only in one section. We have carefully addressed this issue by using antibodies and chromogens that are compatible with co-immunostaining in the same section. We have thus developed an image analysis technique that unambiguously identifies fibrocytes. Moreover, defining tissue fibrocytes as CD34⁺ collagen I⁺ cells (11) may lead to fibrocytes underestimation, which is consistent with previous data showing a downregulation of CD34 expression when fibrocytes differentiate in culture (12). In the

connection, the present data confirming the very low density of CD34⁺ FSP1⁺ cells in bronchial specimens thus are in agreement with those of Wright *et al.* Fibrocytes are commonly defined as cells co-expressing CD45 and collagen I (23). The expression of a hematopoietic marker, such as CD45, is one of the minimum criteria for fibrocyte identification (23) and has been used in the present study. However, since immunohistochemistry for collagen I fails to unambiguously identify collagen I⁺ cells in our experiments (data not shown), as well as in another report (24), we rather used the FSP1 marker, as a co-marker with CD45 for fibrocyte identification, as previously extensively described (13-16). FSP1 (25), also known as S100A4, is used as a marker for lung fibroblasts (24). Most of pulmonary FSP1⁺ cells express collagen I (24, 26), and the number of FSP1⁺ cells correlates with the extent of lung fibrosis in a murine model of fibrosis, suggesting that these cells contribute to collagen deposition (24). In addition, we have shown that almost all the CD45⁺ FSP1⁺ cells purified from circulating PBMC also express collagen I after 14 days of cell differentiation *in vitro* (Fig E2). It thus appears that the term of tissue fibrocyte is more accurate for double positive cells for CD45 and FSP1. Since FSP1 expression has been initially identified in fibroblasts (25) but was subsequently characterized in immune cells such as T and B lymphocytes (13), we paid a special attention to co-immunostain FSP1 with CD3, or CD19. In doing this, we showed that T lymphocytes co-expressing CD3 and FSP1 represented only a minor subset of CD45⁺ FSP1⁺ cells, the density of which did not change in COPD patients. We also showed that no B lymphocyte co-expressing CD19 and FSP1 was present in either distal or proximal human bronchi from both control subjects and COPD patients. Finally, FSP1 expression has also been characterized in macrophages (26). However, numerous macrophage markers, such as CD68, CD163, CD204, CD206, CD209 are also expressed by fibrocytes (27-29). It is thus impossible to properly differentiate fibrocytes from macrophages using immunohistochemistry even if a collagen I⁺ CD45⁺ double staining would have been suitable.

372

373 Our results may argue in favor of a potential deleterious role of tissue fibrocytes in COPD. Indeed,

374 the greater the density of bronchial fibrocytes, the lower the FEV1 value or the FEV1/FVC ratio.

375 Likewise, the greater the density of bronchial fibrocytes, the larger the bronchial wall thickness or

376 the pulmonary air trapping. We previously pointed out a potential detrimental role of blood

377 fibrocytes, since a high concentration of fibrocytes, in the peripheral circulation of COPD patients

378 during an acute exacerbation, was associated with a higher mortality (10). Moreover, blood

379 fibrocytes were present at a high level in frequent exacerbating patients (10). Since small airways

380 are the major site of airway obstruction in COPD (30-32), the observation that tissue fibrocytes

381 density, assessed in the present study, was higher in distal than in proximal airways makes sense.

382 The correlation between the concentration of circulating fibrocytes and the density of distal

383 bronchial fibrocytes may indicate that fibrocytes, which are recruited in the blood during an acute

384 exacerbation (10), subsequently migrate to the airways and participate to the tissue remodeling

385 process, such as peribronchial fibrosis leading to airway obstruction and air trapping. Indeed, once

386 recruited into the lungs, fibrocytes may play various roles, including matrix secretion and

387 degradation, pro-fibrotic cytokines production and activation of contractile force (33). Finally, the

388 lower number of cell death in fibrocytes cultured with BEC from COPD patients combined with

389 the elevated density of fibrocytes at the proximity of the epithelium in tissue samples from COPD

390 patients, would suggest that secretion from epithelial cells in a COPD microenvironment provide

391 pro-survival signals for tissue fibrocytes and could explain, at least partially, bronchial

392 accumulation of fibrocytes in COPD patients. However, continuous efforts are warranted to clarify

393 the cellular mechanisms by which fibrocytes may participate to obstruction development.

394

The present study has some limitations, which deserve further comments. The specimens for fibrocytes detection were obtained from patients with a diagnosis of lung cancer in 37 of 42 patients. As FSP1 is often expressed in malignant cells (34, 35), one may suggest that it could have an impact on fibrocytes density measured in our study. Since (i) bronchial specimens for fibrocytes analysis were selected from macroscopically normal lung resection material, and (ii) patients with a staging different from pN0 confirmed after surgery were excluded, it is unlikely that malignancy would have been sufficient to explain the increase in fibrocytes density we observed in COPD patients.

In conclusion, by taking advantage of unambiguous fibrocytes identification by co-immunostaining and image analysis, we unveil that COPD patients exhibit a greater density of fibrocytes in distal and proximal airways than control subjects. A high density of tissue fibrocytes is associated with a degraded lung function, airway structural changes and a higher risk of COPD, suggesting a deleterious pathogenic role for fibrocytes in COPD.

409 **Acknowledgments**

410 The authors thank the study participants, the staff of thoracic surgery, radiology, pathology,
 411 respiratory and lung function testing departments from the University Hospital of Bordeaux,
 412 Virginie Niel for technical assistance, the Bordeaux Imaging Center (BIC) for help with imaging
 413 and image analysis. Microscopy was done in the Bordeaux Imaging Center a service unit of the
 414 CNRS-INSERM and Bordeaux University, member of the national infrastructure France
 415 BioImaging supported by the French National Research Agency (ANR-10-INBS-04). The help of
 416 Christel Poujol, Sébastien Marais and Fabrice Cordelières for imaging and the help of Muriel
 417 Cario-André for immunohistochemistry are acknowledged.

418 References

- 419 1. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba
420 FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary
421 disease. *N Engl J Med* 2004; 350: 2645-2653.
- 422 2. GOLD 1998. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis,
423 Management and Prevention of Chronic Obstructive Pulmonary Disease. NIH Publication (updated
424 2011). Accessed May 1, 2012, at <http://www.goldcopd.org>.
- 425 3. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. *Respir Care* 2003;
426 48: 1204-1213; discussion 1213-1205.
- 427 4. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe
428 acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. *Thorax*
429 2005; 60: 925-931.
- 430 5. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol
431 and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med*
432 2007; 356: 775-789.
- 433 6. Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium
434 in chronic obstructive pulmonary disease (UPLIFT trial). *Rev Port Pneumol* 2009; 15: 137-140.
- 435 7. Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE,
436 Investigators S. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary
437 disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
438 *Lancet* 2016; 387: 1817-1826.
- 439 8. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette
440 smokers. *N Engl J Med* 1974; 291: 755-758.
- 441 9. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte
442 subpopulation that mediates tissue repair. *Mol Med* 1994; 1: 71-81.
- 443 10. Dupin I, Allard B, Ozier A, Maurat E, Ousova O, Delbrel E, Trian T, Bui HN, Dromer C, Guisset O,
444 Blanchard E, Hilbert G, Vargas F, Thumerel M, Marthan R, Girodet PO, Berger P. Blood fibrocytes
445 are recruited during acute exacerbations of chronic obstructive pulmonary disease through a
446 CXCR4-dependent pathway. *J Allergy Clin Immunol* 2016; 137: 1036-1042 e1037.
- 447 11. Wright AK, Newby C, Hartley RA, Mistry V, Gupta S, Berair R, Roach KM, Saunders R, Thornton T,
448 Shelley M, Edwards K, Barker B, Brightling CE. MDSC-like fibrocytes are increased and
449 associated with preserved lung function in COPD. *Allergy* 2016.
- 450 12. Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S. Identification of circulating fibrocytes as precursors
451 of bronchial myofibroblasts in asthma. *J Immunol* 2003; 171: 380-389.
- 452 13. Mitsuhashi A, Goto H, Saijo A, Trung VT, Aono Y, Ogino H, Kuramoto T, Tabata S, Uehara H, Izumi
453 K, Yoshida M, Kobayashi H, Takahashi H, Gotoh M, Kakiuchi S, Hanibuchi M, Yano S, Yokomise
454 H, Sakiyama S, Nishioka Y. Fibrocyte-like cells mediate acquired resistance to anti-angiogenic
455 therapy with bevacizumab. *Nat Commun* 2015; 6: 8792.
- 456 14. Sangaletti S, Tripodo C, Cappetti B, Casalini P, Chiodoni C, Piconese S, Santangelo A, Parenza M,
457 Arioli I, Miotti S, Colombo MP. SPARC oppositely regulates inflammation and fibrosis in
458 bleomycin-induced lung damage. *Am J Pathol* 2011; 179: 3000-3010.
- 459 15. Rock JR, Barkauskas CE, Cronic MJ, Xue Y, Harris JR, Liang J, Noble PW, Hogan BL. Multiple
460 stromal populations contribute to pulmonary fibrosis without evidence for epithelial to
461 mesenchymal transition. *Proc Natl Acad Sci U S A* 2011; 108: E1475-1483.
- 462 16. Aono Y, Kishi M, Yokota Y, Azuma M, Kinoshita K, Takezaki A, Sato S, Kawano H, Kishi J, Goto H,
463 Uehara H, Izumi K, Nishioka Y. Role of platelet-derived growth factor/platelet-derived growth
464 factor receptor axis in the trafficking of circulating fibrocytes in pulmonary fibrosis. *Am J Respir*
465 *Cell Mol Biol* 2014; 51: 793-801.

17. Coste F, Dournes G, Dromer C, Blanchard E, Freund-Michel V, Girodet PO, Montaudon M, Baldacci F, Picard F, Marthan R, Berger P, Laurent F. CT evaluation of small pulmonary vessels area in patients with COPD with severe pulmonary hypertension. *Thorax* 2016; 71: 830-837.
18. Dournes G, Laurent F, Coste F, Dromer C, Blanchard E, Picard F, Baldacci F, Montaudon M, Girodet PO, Marthan R, Berger P. Computed tomographic measurement of airway remodeling and emphysema in advanced chronic obstructive pulmonary disease. Correlation with pulmonary hypertension. *Am J Respir Crit Care Med* 2015; 191: 63-70.
19. Girodet PO, Dournes G, Thumerel M, Begueret H, Dos Santos P, Ozier A, Dupin I, Trian T, Montaudon M, Laurent F, Marthan R, Berger P. Calcium Channel Blocker Reduces Airway Remodeling in Severe Asthma. A Proof-of-Concept Study. *Am J Respir Crit Care Med* 2015; 191: 876-883.
20. Montaudon M, Berger P, de Dietrich G, Braquelaire A, Marthan R, Tunon-de-Lara JM, Laurent F. Assessment of airways with three-dimensional quantitative thin-section CT: in vitro and in vivo validation. *Radiology* 2007; 242: 563-572.
21. Trian T, Allard B, Dupin I, Carvalho G, Ousova O, Maurat E, Bataille J, Thumerel M, Begueret H, Girodet PO, Marthan R, Berger P. House dust mites induce proliferation of severe asthmatic smooth muscle cells via an epithelium-dependent pathway. *Am J Respir Crit Care Med* 2015; 191: 538-546.
22. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. *Eur Respir J* 2006; 28: 523-532.
23. Reilkoff RA, Bucala R, Herzog EL. Fibrocytes: emerging effector cells in chronic inflammation. *Nat Rev Immunol* 2011; 11: 427-435.
24. Lawson WE, Polosukhin VV, Zoia O, Stathopoulos GT, Han W, Plieth D, Loyd JE, Neilson EG, Blackwell TS. Characterization of fibroblast-specific protein 1 in pulmonary fibrosis. *Am J Respir Crit Care Med* 2005; 171: 899-907.
25. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, Neilson EG. Identification and characterization of a fibroblast marker: FSP1. *J Cell Biol* 1995; 130: 393-405.
26. Inoue T, Plieth D, Venkov CD, Xu C, Neilson EG. Antibodies against macrophages that overlap in specificity with fibroblasts. *Kidney Int* 2005; 67: 2488-2493.
27. Hu X, DeBiasi EM, Herzog EL. Flow Cytometric Identification of Fibrocytes in the Human Circulation. *Methods Mol Biol* 2015; 1343: 19-33.
28. Pilling D, Fan T, Huang D, Kaul B, Gomer RH. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. *PLoS One* 2009; 4: e7475.
29. Bianchetti L, Barczyk M, Cardoso J, Schmidt M, Bellini A, Mattoli S. Extracellular matrix remodelling properties of human fibrocytes. *J Cell Mol Med* 2012; 16: 483-495.
30. Cosio M, Ghezzi H, Hogg JC, Corbin R, Loveland M, Dosman J, Macklem PT. The relations between structural changes in small airways and pulmonary-function tests. *N Engl J Med* 1978; 298: 1277-1281.
31. Hasegawa M, Nasuhara Y, Onodera Y, Makita H, Nagai K, Fuke S, Ito Y, Betsuyaku T, Nishimura M. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2006; 173: 1309-1315.
32. Hogg JC, McDonough JE, Suzuki M. Small airway obstruction in COPD: new insights based on micro-CT imaging and MRI imaging. *Chest* 2013; 143: 1436-1443.
33. Dupin I, Contin-Bordes C, Berger P. Fibrocytes in Asthma and COPD: Variations on the Same Theme. *Am J Respir Cell Mol Biol* 2017.
34. Ilg EC, Schafer BW, Heizmann CW. Expression pattern of S100 calcium-binding proteins in human tumors. *Int J Cancer* 1996; 68: 325-332.
35. Xue C, Plieth D, Venkov C, Xu C, Neilson EG. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. *Cancer Res* 2003; 63: 3386-3394.

Fig legends

Fig 1. Detection of CD45⁺ FSP1⁺ cells.

A, Left column, CD45 (green) and fibroblast-specific protein 1 (FSP1, red) stainings. Middle column, images for CD45 (top panel) and FSP1 (bottom panel) stainings are obtained after color deconvolution. Right column, segmented images are obtained for CD45 (top panel) and FSP1 stainings (bottom panel) after segmentation by a binary threshold. B, Merged segmented image. C, Higher magnification of the segmented image in B. The yellow arrowheads and the white arrows indicate respectively CD45⁺ FSP1⁺ cells and CD45⁺ cells.

Fig 2. Increased fibrocyte density of in distal airways of COPD patients.

A, Representative staining of CD45 (green) and FSP1 (red) in distal bronchial tissue specimens from control subject (left) and COPD patient (right). The yellow arrowheads indicate fibrocytes, defined as CD45⁺ FSP1⁺ cells. B, Quantification of fibrocyte density (normalized by the sub-epithelial area) in one specimen/patient. *: P<0.05, Mann Whitney test. C, Comparison of sub-epithelial areas in control subjects and COPD patients. B, C, medians are represented as horizontal lines.

Fig 3. Increased fibrocyte density in proximal airways of COPD patients.

A, Representative staining of CD45 (green) and FSP1 (red) in proximal bronchial tissue specimens from control subject (left) and COPD patient (right). The yellow arrowheads indicate fibrocytes, defined as CD45⁺ FSP1⁺ cells. B, Quantification of fibrocyte density (normalized by the sub-epithelial area) in one specimen/patient. *: P<0.05, Mann Whitney test. C, Comparison of sub-

epithelial areas in control subjects and COPD patients. B, C, medians are represented as horizontal lines.

Fig 4. Relationships between fibrocyte density, lung function parameters and CT parameters.

A-C, Relationships between FEV1/FVC (A), PaO₂ (B), MLA during expiration (C) and the density of CD45⁺ FSP1⁺ cells in distal airways measured in control subjects (black circles) and COPD patients (open circles). D-F, Relationships between FEV1 (D), WT4 (E), WT5 (F) and the density of CD45⁺ FSP1⁺ cells in proximal airways measured in control subjects (black circles) and COPD patients (open circles). Correlation coefficient (r) and significance level (P value) were obtained by using nonparametric Spearman analysis.

Fig 5. Diagnosis accuracy of high fibrocyte density for COPD

A-B, Receiver operating characteristic (ROC) curves for control subjects and COPD patients with fibrocyte density measured in distal (A) or proximal (B) tissue specimens was built in order to predict COPD.

Table 1: Patient characteristics

	COPD	Control	P value
N	17	25	
Age (yrs.)	66.2 ± 9.5	61.7 ± 8.1	0.11
Sex (Men/Women)	11/6	5/20	0.008
Body-mass index (kg/m ²)	24.7 ± 4.1	26.5 ± 6.9	0.34
Current smoker (Y/N)	2/15	10/15	0.09
Former smoker (Y/N)	15/2	8/17	0.0004
Pack years (no.)	43.7 ± 22.8	18.1 ± 16.8	0.0007
LFT			
FEV ₁ (% pred.)	57.2 ± 22.5	100.0 ± 16.7	<0.0001
FEV ₁ /FVC ratio (%)	53.2 ± 16.3	78.0 ± 8.0	<0.0001
FVC (% pred.)	82.0 ± 15.4	107 ± 15.8	<0.0001
RV (% pred.)	168 ± 68.8	112 ± 27.8	0.0007
TLCO (% pred.)	53.4 ± 22.6	81.8 ± 20.4	0.0003
Six-minute walk test distance (m)	472 ± 67	503 ± 69	0.19
Arterial blood gases			
PaO ₂ (mm Hg)	78.0 ± 11.2	85.1 ± 13.2	0.08
PaCO ₂ (mm Hg)	40.7 ± 7.7	35.7 ± 2.8	0.01
CT parameters			
Bronchi:			
WA4 %	4.2 ± 0.4	3.8 ± 0.6	0.06
WT4 (mm)	1.7 ± 0.2	1.5 ± 0.2	0.03
WA5 %	4.2 ± 0.4	3.2 ± 0.4	<0.0001
WT5 (mm)	1.5 ± 0.2	1.3 ± 0.2	0.02
Emphysema:			
LAA (%)	21.9 ± 16.6	4.2 ± 4.0	<0.0001
Air trapping:			
MLA E (HU)	-858 ± 23	-817 ± 38	0.002
MLA I (HU)	-865 ± 24	-821 ± 33	0.0001
MLA I-E (HU)	-7.5 ± 12	-7.7 ± 31	0.52
Pulmonary vessels:			
%CSA _{<5}	0.35 ± 0.10	0.54 ± 0.20	0.0003
%CSA ₅₋₁₀	0.11 ± 0.02	0.15 ± 0.04	0.0008
CSN _{<5}	0.28 ± 0.03	0.47 ± 0.19	0.0004
CSN ₅₋₁₀	0.016 ± 0.004	0.023 ± 0.006	0.0008

Plus-minus values are means $\pm$ SD. LFT, lung function test; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; RV, residual volume; TLCO, Transfer Lung capacity of Carbon monoxide, PaO₂, partial arterial oxygen pressure, PaCO₂, partial arterial carbon dioxide pressure; WA, mean wall area; LA, mean lumen area, WA%, mean wall area percentage; WT, wall thickness; LAA, low-attenuation area; MLA E or I, mean lung attenuation value during expiration or inspiration. MLA I-E, difference between inspiratory and expiratory mean lung attenuation value. %CSA_{<5}, percentage of total lung area taken up by the cross-sectional area of pulmonary vessels less than 5 mm²; %CSA₅₋₁₀, percentage of total lung area taken up by the cross-sectional area of pulmonary vessels between 5 and 10 mm²; CSN_{<5}, number of vessels less than 5 mm² normalized by total lung area; CSN₅₋₁₀, number of vessels between 5 and 10 mm² normalized by total lung area; NR: not relevant. P values were calculated with the use of a two-sided independent t-test for variables with a parametric distribution, Fisher's exact test for comparison of proportions, and the Mann-Whitney U test for comparison of nonparametric variables.

Table 2: Association of high level of density of tissue fibrocytes with COPD

Type of tissue	n	AUC $\pm$ SD	P value	Cut-off value	Sensitivity [IC]	Specificity [IC]
Distal	32	0.76 $\pm$ 0.09	0.04	72	0.83 [0.70-0.96]	0.70 [0.54-0.86]
Proximal	35	0.72 $\pm$ 0.09	0.02	32	0.79 [0.65-0.92]	0.67 [0.51-0.82]

567
568 Data are absolute number with [95% confidence interval] and plus-minus values are means $\pm$ SD.
569 AUC, Area Under ROC Curve; ROC, Receiver Operating Characteristic; SD, standard deviation.
570 P values, sensitivity and specificity were evaluated for ROC curve analysis.

571 Figures

Fig 1

Fig 2

Fig 3

Fig 4

Fig 5

Fibrocyte accumulation in bronchi: a cellular hallmark of COPD

Isabelle Dupin^{1,2,*}, Matthieu Thumerel^{1,2,3,*}, Elise Maurat^{1,2}, Florence Coste^{1,2}, Hugues Begueret³, Thomas Trian^{1,2}, Michel Montaudon^{1,2,3}, Roger Marthan^{1,2,3}, Pierre-Olivier Girodet^{1,2,3}, Patrick Berger^{1,2,3}

Online Data Supplement

Supplemental Material and Methods

Study Populations

Subjects aged more than 40 years were eligible for enrolment if they required thoracic surgery for lobectomy for cancer pN0, lung transplantation or lung volume reduction. A total of 17 COPD patients, with a clinical diagnosis of COPD according to the GOLD guidelines (1) and 25 non COPD subjects (“control subjects”) with normal lung function testing (*i.e.*, FEV₁/FVC > 0.70) and no chronic symptoms (cough or expectoration) were recruited from the University Hospital of Bordeaux. Main exclusion criteria for both COPD patients and control subjects were history of asthma, lung fibrosis, idiopathic pulmonary hypertension and chronic viral infections (hepatitis, HIV). The main withdrawal criterion for subjects included for lobectomy due to cancer was a staging different from pN0 confirmed after surgery.

To study fibrocyte survival *in vitro*, blood samples were obtained from a separate cohort of COPD patients. These patients were recruited from the COBRA cohort (“Cohorte Obstruction

Bronchique et Asthme”; Bronchial Obstruction and Asthma Cohort; sponsored by the French National Institute of Health and Medical Research, INSERM), as outpatients in the Clinical Investigation Centre of the University Hospital of Bordeaux (Tables E3 and E5).

To assess the role of epithelium on fibrocyte survival *in vitro*, macroscopically normal, lung resection material was ethically obtained by lobectomy from a separate group of patients categorized into COPD and control groups as per GOLD criteria (Table E4).

All subjects provided written informed consent to participate to the study. All clinical data were collected in the Clinical Investigation Center (CIC1401) from the University Hospital of Bordeaux. The study protocol was approved by the research ethics committee (“CPP”) and the French National Agency for Medicines and Health Products Safety (“ANSM”).

Study design

The study protocol was approved by the local research ethics committee on May 30, 2012 and the French National Agency for Medicines and Health Products Safety on May 22, 2012. All clinical investigations have been conducted according to the principles expressed in the Declaration of Helsinki. All subjects provided written informed consent. The clinical trial was conducted from April 2013 (1st patient, 1st visit) to May 2016 (last patient, last visit). As already indicated, all patients undergoing surgery were thus recruited from the Department of Thoracic Surgery of the University Hospital. The study was sponsored and funded by the University Hospital of Bordeaux (*i.e.* “CHU de Bordeaux”). All authors were academic and made the decision to submit the manuscript for publication and vouch for the accuracy and integrity of the contents. The study has been registered at ClinicalTrials.gov under the N° NCT01692444 (*i.e.* “Fibrochir” study).

The study design is summarized in Fig E1. The pre-inclusion visit (V1) before surgery, consisted of patient information and signature of the informed consent followed by a clinical evaluation (*i.e.*, pulmonary auscultation, assessment of the WHO score, history of previous 12 months, smoking status, current treatment...). A full-body CT-scan with injection, was performed as part of the classical disease management but was preceded by two complementary thoracic acquisitions at expiration and inspiration without injection within the framework of the study. The patients also underwent echocardiography and lung function testing using body plethysmography, lung transfer capacity (TLCO) and arterial gas. The inclusion visit (V2), the day of surgery, consisted of a clinical evaluation (*i.e.*, control assessment test (CAT), St Georges Quality of Life Questionnaire (SGQLQ) and six-minute walk test) and venous blood sample (50 ml) for fibrocytes analysis. After thoracic surgery (lobectomy or pneumonectomy), a pulmonary sample from a grossly normal part of the surgical specimen is included in paraffin for subsequent analysis of the bronchial fibrocytes. Due to low quality of some tissue sections, fibrocyte density quantification was impossible in 10 distal specimens and 7 proximal specimens (Fig E1), which were excluded from peribronchial fibrocyte analysis. During hospital stay, clinical data was collected such as pTNM status for cancer patients. A visit one month $\pm$ 15 days after surgery (V3) consisted of spirometric evaluation. The last visit one year $\pm$ 15 days after surgery (V4) consisted of clinical (CAT, SGQLQ and six-minute walk test) and functional (plethysmography, TLCO, arterial gas) evaluations. COPD patients and control subjects performed the whole series of “Fibrochir” visits, with the exception of 2 COPD patients who provided written informed consent for the use of biological samples and clinical data for research and underwent only two visits (corresponding to V1 and V2) including the surgical pulmonary sample for peribronchial fibrocyte analysis.

Bronchial fibrocytes identification

A sub-segmental bronchus sample (for proximal tissue) as well as fragments of distal parenchyma were obtained from macroscopically normal lung resection material. The samples were embedded in paraffin and sections of 2.5 μm thick were cut, as described previously (2). Sections were deparaffinized through three changes of xylene and through graded alcohols to water. Heat induced antigen retrieval was performed using citrate buffer, pH 6 (Fisher Scientific, Illkirch, France) in a Pre-Treatment Module (Agilent, Les Ulis, France). Endogenous peroxidase and alkaline phosphatases (AP) were blocked for 10 min using Dual Enzyme Block (Diagomics, Blagnac, France). Nonspecific binding was minimized by incubating the sections with 4% Goat Serum (Agilent) for 30 min. The sections were stained with both rabbit anti-FSP1 polyclonal antibody (Agilent) and mouse anti-CD45 monoclonal antibody (BD Biosciences, San Jose, CA), or mouse anti-CD3 monoclonal antibody (Agilent), mouse anti-CD19 monoclonal (Agilent), mouse anti-CD34 monoclonal antibody (Agilent) or appropriate isotype controls, rabbit IgG (Fisher Scientific) and mouse IgG1 (R&D Systems, Lille, France) at the same concentration. For CD45-FSP1 double staining, the sections were re-incubated with HRP-Polymer anti-Mouse and AP Polymer anti-Rabbit antibodies (Diagomics). Sections were developed with the chromogenic substrates, GBI-Permanent Red and Emerald. For CD3-FSP1, CD19-FSP1 and CD34-FSP1 double staining, the sections were re-incubated with HRP anti-Mouse (Agilent) and with Alexa488-conjugated anti-Rabbit (Fisher Scientific) antibodies. Immunoreactivity was detected by using the DAB System (Agilent) for CD3, CD19 or CD34 staining and by fluorescence for FSP1 staining.

The sections were imaged using a slide scanner Nanozoomer 2.0HT with fluorescence imaging module (Hamamatsu Photonics, Massy, France) using objective UPS APO 20X NA 0.75 combined to an additional lens 1.75X, leading to a final magnification of 35X. Virtual slides were acquired with a TDI-3CCD camera. Fluorescent acquisitions were done with a mercury

lamp (LX2000 200W - Hamamatsu Photonics) and the set of filters adapted for DAPI and Alexa

488. Bright field and fluorescence images were acquired with the NDP-scan software (Hamamatsu) and processed with ImageJ. Quantification of dual positive cells for FSP1 and CD45 was performed, as described in Fig 1. A color deconvolution plugin was used on bright field image to separate channels corresponding to GBI-Permanent Red and Emerald double staining, and a binary threshold was then applied to these images (Fig 1A). Tissue fibrocytes were defined as cells dual positive for cytoplasmic FSP1 and plasma membrane CD45 double staining on the merged threshold image (Fig 1B-C). The lamina propria contour was manually determined on bright field image and the area was calculated. For distal bronchi, the lumen area was also determined and only bronchi less than 2 mm in diameter were analyzed as described by J.C. Hogg *et al* (3). The density of FSP1⁺ CD45⁺ cells was defined by the ratio between the number of dual positive cells in the lamina propria divided by lamina propria area. Quantification of dual positive cells for FSP1 and CD3, FSP1 and CD19 or FSP1 and CD34 was performed, as described above with some modification: a color deconvolution plugin was used on bright field image to select the channel corresponding to DAB signal (for CD3, CD19 or CD34 staining), and a binary threshold was then applied to this image and fluorescence image corresponding to FSP1 staining. Tissue area and cell measurements were all performed in a blinded fashion for patients' characteristics.

Quantitative computed tomography

CT scans were performed on a Somatom Sensation Definition 64 (Siemens, Erlangen, Germany) at full inspiration and expiration, as described previously (4-7). Briefly, quantitative analysis was performed by using dedicated and validated software: Automatic quantification of bronchial wall area (WA), lumen area (LA), WA/LA (WA%) and wall thickness (WT) was

obtained on orthogonal bronchial cross sections by using the Laplacian-of-Gaussian algorithm and homemade software (8, 9); Automatic quantification of both emphysema and air trapping was assessed using Myrian software (Intrasense, Montpellier, France) and both low attenuation area per cent (LAA%) (4, 5) and mean lung attenuation (MLA) during expiration (6, 7); Quantification of pulmonary vessels was obtained from CT images, as previously described (4). Briefly, CT set of images reconstructed with sharp algorithm (B70f) were analyzed by using the ImageJ software version 1.40g (a public domain Java image program available at <http://rsb.info.nih.gov/ij/>). The small pulmonary vessels measurements were made automatically as described elsewhere (4, 10-12). The cross section area (CSA) and cross section number (CSN) of small pulmonary vessels were quantified separately at the subsegmental and at the sub-subsegmental levels (4, 12). The subsegmental and sub-subsegmental levels are defined by a vessel area between 5 and 10 mm² and less than 5 mm², respectively. Finally, quantifications were obtained after normalization by the corresponding lung section area at each CT slice: the cross sectional area of small pulmonary vessel less than 5 mm² (%CSA_{<5}). Four measurements were obtained after normalization by the corresponding lung section area at each CT slice: the cross sectional area of small pulmonary vessel between 5 to 10 mm² (%CSA₅₋₁₀), and less than 5 mm² (%CSA_{<5}), the mean number of cross-sectioned vessels CSN₅₋₁₀ and CSN_{<5}.

Circulating fibrocytes identification

Non-adherent non-T (NANT) cells were purified from Peripheral Blood Mononuclear Cells (PBMC) separated from the whole blood, and circulating fibrocytes were identified as double positive cells for the surface marker CD45 and the intracellular marker collagen I by flow cytometry, as described previously (13). Briefly, PBMC were first separated from the whole blood by Ficoll-Hypaque (Dutscher, Brumath, France) density gradient centrifugation. The non-adherent mononuclear cell fraction was taken and washed in cold PBS containing 0.5%

bovine serum albumin (BSA, Sigma-Aldrich) and 2 mM Ethylene Diamine Tetra-acetic Acid (EDTA, Invitrogen). T-cells were further depleted with anti-CD3 monoclonal antibody (Miltenyi Biotech, Paris, France). Cells were fixed overnight with Cytofix/Cytoperm (eBioscience, Paris, France), washed in permeabilization buffer (eBioscience) and incubated either with mouse anti-human collagen I antibody (Millipore, St-Quentin-en-Yvelines, France) or with matched IgG1 isotype control (Santa Cruz Biotechnology, Heidelberg, Germany), followed by fluorescein isothiocyanate (FITC)-conjugated anti-mouse antibodies (Beckman Coulter, Villepinte, France). Next, the cell pellet was incubated either with allophycocyanin (APC)-conjugated anti-CD45 antibodies (BD Biosciences, San Jose, CA) or with matched APC-conjugated IgG1 isotype control (BD Biosciences). The cell suspension was analyzed with a BD FACSCanto II flow cytometer (BD Biosciences). Offline analysis was performed with FACSDiva (BD Biosciences) and FlowJo (Tree Star, Ashland, OR) software. The negative threshold for CD45 was set using a matched APC-conjugated IgG1 isotype control, and all subsequent samples were gated for the CD45 positive region. Cells gated for CD45 were analyzed for collagen I expression, with negative control thresholds set using FITC-stained cells. Specific staining for collagen I was determined as an increase in positive events over this threshold. Fibrocytes numbers were expressed as both a percentage of total PBMC counts and as absolute number of cells.

Bronchial epithelial supernatants

Human bronchial epithelial cells (BEC) were derived from bronchial specimens as described previously (14). Bronchial epithelial tissue was cultured in bronchial epithelial growth medium (Stemcell, Grenoble, France) in a flask (0.75 cm²). After confluence, basal BEC were plated (2.10⁵ cells per well) on uncoated nucleopore membranes (24-mm diameter, 0.4-μm pore size, Transwell Clear; Costar, Cambridge, Mass) in ALI medium (Stemcell) applied at the basal side only to establish the air-liquid interface. Cells were maintained in culture for 21 days to obtain

a differentiated cell population with a mucociliary phenotype. Basal epithelial supernatant was collected every 2-3 days and used for further experiments.

Fibrocyte differentiation and survival

A total of $2 \cdot 10^6$ NANT cells resuspended in 0.2 ml DMEM (Fisher Scientific), containing 4.5 g/l glucose and glutaMAX, supplemented with 20% fetal calf serum (Biowest, Riverside, USA), penicillin/streptomycin and MEM non-essential amino acid solution (Sigma-Aldrich), was added to each well of a 6 well plate. After one week in culture, fibrocyte differentiation was induced by changing the medium for a serum-free medium (Fig E2), or for a serum-free medium containing 50% of basal epithelium supernatant (Fig E10). Mediums were changed every 2-3 days. After 2 weeks in culture, the cells were detached by accutase treatment (Fisher Scientific), fixed overnight with Cytofix/Cytoperm and washed in permeabilization buffer. Cells were incubated either with rabbit anti-FSP1 polyclonal antibody (Agilent) or with matched IgG isotype control (Fisher Scientific), followed by Phycoerythrin (PE)-conjugated anti-rabbit antibody (Santa Cruz Biotechnology, Heidelberg, Germany). Next, the cell pellet was incubated either with FITC-conjugated mouse anti-human collagen I antibody (Millipore) or with matched FITC-conjugated IgG1 isotype control (Millipore) and with APC-conjugated anti-CD45 antibodies or with matched APC-conjugated IgG1 isotype control. The cell suspension was analyzed with a BD FACSCanto II flow cytometer. Cells gated for CD45 and FSP1 were analyzed for collagen-1 expression, with negative control thresholds set using isotype-stained cells. Specific staining for collagen-1 was determined as an increase in positive events over this threshold.

Propidium iodide (Fisher Scientific) was used for the detection of dying cells. After 2 weeks in culture, cells detached by accutase treatment were used to prepare single cell suspension at

1.10^6 cells/ml. After addition of propidium iodide, the dying cells (PI⁺ cells) were detected by flow cytometry (BD Biosciences).

Statistical analysis

Primary outcome was the density of bronchial fibrocytes in both distal and proximal airways. Secondary outcomes were lung function parameters, CT parameters and the percentage of blood fibrocytes in PBMC. The statistical analysis was performed with Prism 6 software (GraphPad, La Jolla, CA) and NCSS software (NCSS 2001, Kaysville, UT, USA). Values are presented as medians with individual plots or means $\pm$ SD. Statistical significance, defined as $P < 0.05$, was analyzed by Fisher's exact tests for comparison of proportions, by two-sided independent t-tests for variables with a parametric distribution, and, by Mann–Whitney U tests, Wilcoxon tests and Spearman correlation coefficients for variables with a non-parametric distribution. Receiver operating characteristic (ROC) curves were built with NCSS software (NCSS 2001, Kaysville, UT, USA) and ROC analysis was performed to determine areas under the curve (AUC) and cut-off values for the best fibrocytes density in distal and proximal tissue specimens to predict COPD. Those 2 cut-off values were then used to evaluate the association between COPD and a high density of tissue fibrocytes using a univariate logistic regression analysis.

References

1. GOLD 1998. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NIH Publication (updated 2011). Accessed May 1, 2012, at <http://www.goldcopd.org>.
2. Begueret H, Berger P, Vernejoux JM, Dubuisson L, Marthan R, Tunon-de-Lara JM. Inflammation of bronchial smooth muscle in allergic asthma. *Thorax* 2007; 62: 8-15.
3. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med* 2004; 350: 2645-2653.
4. Coste F, Dournes G, Dromer C, Blanchard E, Freund-Michel V, Girodet PO, Montaudon M, Baldacci F, Picard F, Marthan R, Berger P, Laurent F. CT evaluation of small pulmonary vessels area in patients with COPD with severe pulmonary hypertension. *Thorax* 2016; 71: 830-837.
5. Dournes G, Laurent F, Coste F, Dromer C, Blanchard E, Picard F, Baldacci F, Montaudon M, Girodet PO, Marthan R, Berger P. Computed tomographic measurement of airway remodeling and emphysema in advanced chronic obstructive pulmonary disease. Correlation with pulmonary hypertension. *Am J Respir Crit Care Med* 2015; 191: 63-70.
6. Girodet PO, Dournes G, Thumerel M, Begueret H, Dos Santos P, Ozier A, Dupin I, Trian T, Montaudon M, Laurent F, Marthan R, Berger P. Calcium Channel Blocker Reduces Airway Remodeling in Severe Asthma. A Proof-of-Concept Study. *Am J Respir Crit Care Med* 2015; 191: 876-883.
7. Berger P, Laurent F, Begueret H, Perot V, Rouiller R, Raherison C, Molimard M, Marthan R, Tunon-de-Lara JM. Structure and function of small airways in smokers: relationship between air trapping at CT and airway inflammation. *Radiology* 2003; 228: 85-94.
8. Berger P, Perot V, Desbarats P, Tunon-de-Lara JM, Marthan R, Laurent F. Airway wall thickness in cigarette smokers: quantitative thin-section CT assessment. *Radiology* 2005; 235: 1055-1064.
9. Montaudon M, Berger P, de Dietrich G, Braquelaire A, Marthan R, Tunon-de-Lara JM, Laurent F. Assessment of airways with three-dimensional quantitative thin-section CT: in vitro and in vivo validation. *Radiology* 2007; 242: 563-572.
10. Uejima I, Matsuoka S, Yamashiro T, Yagihashi K, Kurihara Y, Nakajima Y. Quantitative computed tomographic measurement of a cross-sectional area of a small pulmonary vessel in nonsmokers without airflow limitation. *Jpn J Radiol* 2011; 29: 251-255.
11. Matsuoka S, Washko GR, Dransfield MT, Yamashiro T, San Jose Estepar R, Diaz A, Silverman EK, Patz S, Hatabu H. Quantitative CT measurement of cross-sectional area of small pulmonary vessel in COPD: correlations with emphysema and airflow limitation. *Acad Radiol* 2010; 17: 93-99.
12. Matsuoka S, Washko GR, Yamashiro T, Estepar RS, Diaz A, Silverman EK, Hoffman E, Fessler HE, Criner GJ, Marchetti N, Scharf SM, Martinez FJ, Reilly JJ, Hatabu H, National Emphysema Treatment Trial Research G. Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema. *Am J Respir Crit Care Med* 2010; 181: 218-225.
13. Dupin I, Allard B, Ozier A, Maurat E, Ousova O, Delbrel E, Trian T, Bui HN, Dromer C, Guisset O, Blanchard E, Hilbert G, Vargas F, Thumerel M, Marthan R, Girodet PO, Berger P. Blood fibrocytes are recruited during acute exacerbations of chronic obstructive pulmonary disease through a CXCR4-dependent pathway. *J Allergy Clin Immunol* 2016; 137: 1036-1042 e1037.
14. Trian T, Allard B, Dupin I, Carvalho G, Ousova O, Maurat E, Bataille J, Thumerel M, Begueret H, Girodet PO, Marthan R, Berger P. House dust mites induce proliferation of severe asthmatic smooth muscle cells via an epithelium-dependent pathway. *Am J Respir Crit Care Med* 2015; 191: 538-546.

Supplemental tables

Table E1. Association between distributions of distal tissue fibrocytes and COPD clinical characteristics

	Distal CD45 ⁺ FSP1 ⁺ cells density	
	Spearman r	P value
Age (yrs.)	0.06	0.76
Body-mass index (kg/m ²)	0.09	0.63
Pack years (no.)	0.21	0.26
LFT		
FEV ₁ (% pred.)	-0.28	0.12
FEV ₁ /FVC ratio (%)	-0.42	0.02
FVC (% pred.)	-0.31	0.09
RV (% pred)	0.30	0.10
TLCO (% pred.)	-0.20	0.31
Six-minute walk test distance (m)	0.14	0.49
Arterial blood gases		
PaO ₂ (mm Hg)	-0.27	0.15
PaCO ₂ (mm Hg)	0.37	0.04
CT parameters		
Bronchi:		
WA4 %	0.12	0.56
WT4 (mm)	0.08	0.68
WA5 %	0.29	0.16
WT5 (mm)	0.17	0.41
Emphysema:		
LAA (%)	0.36	0.056
Air trapping:		
MLA E (HU)	-0.44	0.03
MLA I (HU)	-0.20	0.31
MLA I-E (HU)	0.08	0.72
Pulmonary Vessels		
%CSA _{<5}	-0.21	0.26
%CSA ₅₋₁₀	-0.15	0.44
CSN _{<5}	-0.18	0.33
CSN ₅₋₁₀	-0.16	0.41

LFT, lung function test; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; RV, residual volume; TLCO, Transfer Lung capacity of Carbon monoxide, PaO₂, partial arterial oxygen pressure, PaCO₂, partial arterial carbon dioxide pressure; WA, mean wall area; LA, mean lumen area, WA%, mean wall area percentage; WT, wall thickness; LAA, low-attenuation area; MLA E or I, mean lung attenuation value during expiration or inspiration. MLA I-E, difference between inspiratory and expiratory mean lung attenuation value. %CSA_{<5}, percentage of total lung area taken up by the cross-sectional area of pulmonary vessels less than 5 mm²; %CSA₅₋₁₀, percentage of total lung area taken up by the cross-sectional area of pulmonary vessels between 5 and 10 mm²; CSN_{<5}, number of vessels less than 5 mm² normalized by total lung area; CSN₅₋₁₀, number of vessels between 5 and 10 mm² normalized by total lung area; NR: not relevant. Correlation coefficient (r) and significance level (P value) were obtained by using nonparametric Spearman analysis.

Table E2. Association between distributions of proximal tissue fibrocytes and COPD

clinical characteristics

	Proximal CD45⁺ FSP1⁺ cells density	
	Spearman r	P value
Age (yrs.)	-0.09	0.60
Body-mass index (kg/m ²)	0.32	0.06
Pack years (no.)	0.02	0.91
LFT		
FEV ₁ (% pred.)	-0.33	0.049
FEV ₁ /FVC ratio (%)	-0.28	0.10
FVC (% pred.)	-0.34	0.04
RV (% pred)	0.43	0.01
TLCO (% pred.)	-0.04	0.80
Six-minute walk test distance (m)	-0.14	0.46
Arterial blood gases		
PaO ₂ (mm Hg)	-0.26	0.14
PaCO ₂ (mm Hg)	0.20	0.26
CT parameters		
Bronchi:		
WA4 %	0.50	0.02
WT4 (mm)	0.54	0.005
WA5 %	0.34	0.10
WT5 (mm)	0.42	0.04
Emphysema:		
LAA (%)	0.18	0.34
Air trapping:		
MLA E (HU)	0.07	0.76
MLA I (HU)	0.08	0.68
MLA I-E (HU)	0.28	0.17
Pulmonary Vessels		
%CSA _{<5}	-0.07	0.73
%CSA ₅₋₁₀	-0.06	0.77
CSN _{<5}	-0.03	0.88
CSN ₅₋₁₀	-0.07	0.70

LFT, lung function test; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; RV, residual volume; TLCO, Transfer Lung capacity of Carbon monoxide, PaO₂, partial arterial oxygen pressure, PaCO₂, partial arterial carbon dioxide pressure; WA, mean wall area; LA, mean lumen area, WA%, mean wall area percentage; WT, wall thickness; LAA, low-attenuation area; MLA E or I, mean lung attenuation value during expiration or inspiration. MLA I-E, difference between inspiratory and expiratory mean lung attenuation value. %CSA_{<5}, percentage of total lung area taken up by the cross-sectional area of pulmonary vessels less than 5 mm²; %CSA₅₋₁₀, percentage of total lung area taken up by the cross-sectional area of pulmonary vessels between 5 and 10 mm²; CSN_{<5}, number of vessels less than 5 mm² normalized by total lung area; CSN₅₋₁₀, number of vessels between 5 and 10 mm² normalized by total lung area; NR: not relevant. Correlation coefficient (r) and significance level (P value) were obtained by using nonparametric Spearman analysis.

Table E3. Patient characteristics

	COPD
n	3
Age (yr)	68.7 ± 15.0
Sex (Men/Woman)	2/1
Body-mass index (kg/m ²)	21.0 ± 3.5
Current smoker (Y/N)	2/1
Former smoker (Y/N)	1/2
Pack years (no.)	42.3 ± 24.2
PFT	
FEV ₁ (% pred.)	58.3 ± 22.5
FEV ₁ /FVC ratio (%)	53.3 ± 11.5
FVC (% pred.)	84.0 ± 27.6
Six-minute walk test distance (m)	550 ± 42
Arterial blood gases	
PaO ₂ (mm Hg)	77.0 ± 6.1
PaCO ₂ (mm Hg)	37.0 ± 4.2

Plus-minus values are means ± SD. PFT, pulmonary function test; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; PaO₂, partial arterial oxygen pressure, PaCO₂, partial arterial carbon dioxide pressure.

Table E4. Patient characteristics (for bronchial epithelial supernatants production)

	COPD	Control
n	2	2
Age (yr)	62.5 ± 12.0	70.5 ± 13.4
Sex (Men/Woman)	0/2	2/0
Body-mass index (kg/m ²)	31.5 ± 7.8	24.5 ± 0.7
Current smoker (Y/N)	0/1*	0/2
Former smoker (Y/N)	1/0*	0/2
Pack years (no.)	50.0 ± 70.7	0
PFT		
FEV ₁ (% pred.)	62.5 ± 3.5	113.5 ± 62.9
FEV ₁ /FVC ratio (%)	61.0 ± 0	81.5 ± 0.1

Plus-minus values are means ± SD. PFT, pulmonary function test; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity. * one of the two COPD patients has been professionally exposed to noxious particles.

Table E5. Patient characteristics

	COPD
n	6
Age (yr)	69.2 ± 8.0
Sex (Men/Woman)	2/4
Body-mass index (kg/m ²)	27.7 ± 5.6
Current smoker (Y/N)	4/2
Former smoker (Y/N)	2/4
Pack years (no.)	66.3 ± 24.7
PFT	
FEV ₁ (% pred.)	67.1 ± 22.5
FEV ₁ /FVC ratio (%)	62.1 ± 6.4
FVC (% pred.)	86.2 ± 30.0
Six-minute walk test distance (m)	395 ± 187
Arterial blood gases	
PaO ₂ (mm Hg)	71.1 ± 6.6
PaCO ₂ (mm Hg)	37.1 ± 4.7

Plus-minus values are means ± SD. PFT, pulmonary function test; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; PaO₂, partial arterial oxygen pressure, PaCO₂, partial arterial carbon dioxide pressure.

Supplemental figures legends

Supplementary Fig E1. Study design.

Numbers of patients who were included and had fibrocyte density quantification in proximal and distal airways.

Supplementary Fig E2. CD45⁺ FSP1⁺ cells purified from NANT cells express collagen I after 2 weeks of differentiation in culture.

Representative dot plots of flow cytometry for CD45, FSP1 and collagen I expression. Left panels: total Non-Adherent Non T (NANT) cell population selected on the scatter plot of FSC-A vs SSC-A. Middle panels: a gate (CD45⁺ and FSP1⁺) was drawn in FSP1-PE vs APC-CD45 dot plot to define the Q2 population (positive population for both CD45 and FSP1). Right panels: a gate (collagen I⁺) was drawn in FITC-collagen I (colI) histogram to define the P3 population (positive population for CD45, FSP1 and collagen I). A, isotype control for CD45, FSP1 and collagen I. B, CD45, FSP1 and collagen I stainings. APC: allophycocyanin; FITC: fluorescein isothiocyanate; PE: Phycoerythrin; FSC-A: forward scatter; SSC-A: side scatter.

Supplementary Fig E3. Presence of fibrocytes in peribronchial area outside the smooth muscle layer.

Representative staining of CD45 (green) and FSP1 (red) in distal (left) and proximal (right) bronchial tissue specimens. The lower panels show higher magnification of the small area (black boxes) defined in the upper panels. The smooth muscle layer has been highlighted in orange. The yellow arrowheads indicate fibrocytes, defined as CD45⁺ FSP1⁺ cells.

Supplementary Fig E4. Relationship between the density of CD45⁺ FSP1⁺ cells in proximal airways and that in distal airways.

Densities measured in control subjects and COPD patients are represented respectively with black and open circles. Correlation coefficient (r) and significance level (P value) were obtained by using nonparametric Spearman analysis.

Supplementary Fig E5. CD3⁺ FSP1⁺ cells represent a minor fraction of CD45⁺ FSP1⁺ cells.

A, Representative stainings of CD3 (brown, top panels) and FSP1 (green, middle panels) and merged segmented images (CD3, red and FSP1, green, bottom panels) in distal lung tissue from COPD patient. Middle and right columns represent higher magnification of images in the left column. The yellow arrowheads indicate CD3⁺ FSP1⁺ cells. B, D, Quantification of CD3⁺ FSP1⁺ cells density (normalized by the sub-epithelial area) in distal (B) and proximal (D) tissue specimens from control subjects and COPD patients. C, E, Comparison of sub-epithelial areas in distal (C) and proximal (E) tissue specimens from control subjects and COPD patients. B-D, medians are represented as horizontal lines.

Supplementary Fig E6. CD19⁺ FSP1⁺ cells are detected neither in proximal and nor in distal airways.

A-B, Representative stainings of CD19 (brown, top panels) and FSP1 (green, middle panels) and merged segmented images (CD19, red and FSP1, green, bottom panels) in distal (A) and proximal (B) bronchial tissue specimens from COPD patient. The right columns represent higher magnification of images in the left columns.

Supplementary Fig E7. CD34⁺ FSP1⁺ cells are almost absent in distal airways.

A, Representative stainings of CD34 (brown, top left panel) and FSP1 (green, bottom left panels) and merged segmented image (CD34, red and FSP1, green, right panel) in distal tissue specimen from COPD patient. The yellow arrowhead indicates CD34⁺ FSP1⁺ cells. B, Quantification of CD34⁺ FSP1⁺ cells density (normalized by the sub-epithelial area) in distal tissue specimens from control subjects and COPD patients. Median is represented as horizontal line. C, Percentage of tissue specimens in which CD34⁺ FSP1⁺ cells have been detected (density>0, black bars) or undetected (density=0, white bars) in distal tissue specimens from control subjects and COPD patients.

Supplementary Fig E8. CD34⁺ FSP1⁺ cells are present at a very low level in proximal airways.

A, Representative stainings of CD34 (brown, top left panel) and FSP1 (green, bottom left panels) and merged segmented image (CD34, red and FSP1, green, right panel) in proximal tissue specimen from COPD patient. The yellow arrowhead indicates CD34⁺ FSP1⁺ cells. B, Quantification of CD34⁺ FSP1⁺ cells density (normalized by the sub-epithelial area) in proximal tissue specimens from control subjects and COPD patients. Median is represented as horizontal line. C, Percentage of tissue specimens in which CD34⁺ FSP1⁺ cells have been detected (density>0, black bars) or undetected (density=0, white bars) in proximal tissue specimens from control subjects and COPD patients.

Supplementary Fig E9. Level of circulating fibrocytes and relationship with tissue fibrocytes density.

A, Level of circulating fibrocytes (CD45⁺ ColI⁺ cells), expressed as percentage of PBMC, measured in blood from control subjects ("Cont", n = 22), and COPD patients ("COPD", n=12). Medians are represented as horizontal lines. B, Relationships between the level of circulating fibrocytes and the density of CD45⁺ FSP1⁺ cells in distal airways measured in control subjects (black circles) and COPD patients (open circles). B, C, Correlation coefficient (r) and significance level (P value) were obtained by using nonparametric Spearman analysis.

Supplementary Fig E10. Influence of epithelium on fibrocyte survival.

A, Representative histograms of flow cytometry for Propidium Iodure (PI) fluorescence recorded on fibrocytes exposed to epithelium supernatants, either from control subjects (left panel), or COPD patient (right panel). A gate was drawn to define the population of dead cells (PI⁺ cells). B, Quantification of PI⁺ cells in fibrocytes from COPD patients (n=6) exposed to epithelium supernatants from control subjects (red circles) or COPD patients (blue circles). *: P<0.05, Wilcoxon test.

Figure E1

Figure E2

Q2 : CD45⁺ FSP1⁺ cells

P3 : CD45⁺ FSP1⁺ Coll⁺ cells

Figure E3

Figure E4

Figure E5

Figure E6

Figure E7

Figure E8

Figure E9

Figure E10